Docetaxel in combination with rhumab her2 for the treatment of cancers
CA 2368369 C · Owner: Aventis Pharma S.A. · Inventors: Vogel, Charles L.; Bellet, Robert E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of treating cancer comprising , administering a dose of docetaxel and a dose of rhuMAb HER2 to a patient in need thereof, wherein said dosages have a synergistic therapeutic effect when compared to the administration of docetaxel or rhuMAb HER2 alone.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 7, 2000 and granted March 25, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 7, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 7, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.